The Medipattern Corporation
TSX VENTURE : MKI

The Medipattern Corporation

September 25, 2007 07:05 ET

Medipattern Expands B-CAD™ Line With 7 New Solutions

B-CAD now available in solutions ranging from turn-key to PACS plug-in modules

TORONTO, ONTARIO--(Marketwire - Sept. 25, 2007) -

Attention: Business/Financial Editors:

The Medipattern Corporation (TSX VENTURE:MKI), an award-winning developer of computer-aided detection (CAD) medical imaging software designed to detect cancer and permit a higher standard of care for the millions of patients at risk of cancer, is pleased to announce seven new B-CAD products: six versions of B-CAD for breast ultrasound imaging and one version for breast MRI (magnetic resonance imaging). Medipattern is the first and only company to cross the modality boundary, creating CAD products for breast ultrasound imaging and breast MRI from the same algorithm platform technology. The Company's B-CAD solutions have been found to save time, increase consistency in reading, and document information in greater detail, providing a better record for tracking patients.

The new B-CAD solutions will be shown at RSNA 2007as well as works-in-progress for CAD on whole-breast ultrasound, the next generation in breast ultrasound imaging. CAD is key to effectively reading the multiple images acquired during whole-breast ultrasound. Next-generation B-CAD reads the images in cine loops, automatically detecting and characterizing lesions. CAD results are reviewed by the radiologist, who can edit, and then B-CAD automatically enters all of the evidence and findings into a natural language report.

B-CAD 1.2.1 for breast ultrasound imaging is now available for the US market in a wide range of formats ideal for those customers who either already have PACS or who are new to the PACS environment. The turn-key solution includes a DICOM-network-ready PC with a B-CAD viewer and CAD reporting system, ideal for those facilities just starting to work in a PACS environment. For those facilities that have invested in a large number of workstations, 1.2.1 is available in a software format for loading onto existing equipment. Medipattern is also pleased to announce the release of two software plug-in modules for PACS partners Cedara of Canada and Swedish based Sectra. The modules can plug into new or existing PACS viewers to support the new C4 revision level for Cedara and the multimodality women's health IDS5 workstation from Sectra. B-CAD 1.2.1 delivers ease of workflow, enabling radiologist-customizable methods that easily integrate into the natural reading process. 1.2.1 is capable of analyzing multiple lesions in multiple views for unilateral or bilateral cases, organizing the information into a complete, unified natural language report. B-CAD 1.2.1 is shipping now through Medipattern's US reseller channel and partners.

B-CAD 2.2 for breast ultrasound imaging is available to the rest of the world and is shipping through Medipattern's world-wide distribution channel. Version 2.2 is available in two formats: as a software product intended for Medipattern's resellers to load onto workstations and as a plug-in module for the Sectra IDS5 workstation. B-CAD 2.2 electronically analyzes breast masses using all of the American College of Radiology's BI-RADS® (Breast Imaging Reporting and Data System) feature categories: size, shape, orientation, margin, lesion boundary, echo pattern, post-acoustic features, and calcification in masses. Version 2.2 gathers all of the information required to track multiple lesions and completes the imaging procedure by automatically documenting the results in a pre-formatted report.

Medipattern's morphology CAD for breast MRI will be shown as part of Confirma's Version 5 CADstream™ product at RSNA. It performs detection and characterization of features based on physical shapes or morphology within a breast MRI. Medipattern's morphology CAD, joined with Confirma's kinetic CAD, form a complete approach to reviewing MRI images, detecting lesions via both physical characteristics and dynamic flow characteristics.

"In the past year, Medipattern has grown from a single introductory B-CAD product for ultrasound to a global family of products for different systems and modalities providing flexible solutions for a variety of users, from small clinics through large-scale enterprises," said Janet Sterritt, Vice President of Sales and Marketing. "Equally, our sales channel has grown to include 7 independent global resellers and 11 independent US resellers. Our partnership network has expanded from a single partner to include Carestream, Cedara, Confirma, GE Healthcare, Sectra and SonoCine."

Upcoming Events:

Medipattern will participate in the following events:

- China Ultrasound Conference, September 21 to 25, Beijing, PRC.

- Chicago International Breast Imaging Symposium October 3 to 7, 2007, Chicago, IL.

- JFR, October 20 to 24, Paris, France.

- RSNA, November 25 to 29, 2007, Chicago, IL.

- European Congress of Radiology (ECR), March 7 to 11, Vienna, Austria.

The Medipattern Corporation

Medipattern develops computer-aided detection (CAD) solutions for medical imaging. These products enhance workflow while improving interpretive and diagnostic confidence. The Company's initial clinical applications are B-CAD™ for breast ultrasound and B-CAD MRI™. Both have received awards for innovation in the industry. The B-CAD products use pattern recognition technology to assist radiologists in their efforts to classify and characterize lesions in images of the breast. Medipattern was founded to design software products that detect and identify lesions in breast imaging to support a higher standard of medical care. Please visit the company's website at: www.medipattern.com.

B-CAD™ and B-CAD MRI™ are trademarks of The Medipattern Corporation.
Medipattern® is a registered mark of The Medipattern Corporation. BI-RADS® is a registered trademark of the American College of Radiology.

Forward-looking statements

This document contains forward-looking statements relating to Medipattern's performance, operations, or business environment. These statements are based on what we believe are reasonable assumptions given currently available information and our understanding of Medipattern's current activities. We have tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential", and similar expressions. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that are difficult to predict or control. A number of factors could cause actual outcomes and results to differ materially from those expressed in forward-looking statements. These factors include but are not limited to those set forth in the Company's corporate filings (posted at www.sedar.com). In addition, these forward-looking statements relate to the date on which they are made. The Company disclaims any intention or obligation to update or revise any forward-looking statements for any reason. Readers should not rely on forward-looking statements.

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release and has neither approved nor disapproved of the contents of this release.

Contact Information